0001104659-20-122748.txt : 20201109 0001104659-20-122748.hdr.sgml : 20201109 20201109071941 ACCESSION NUMBER: 0001104659-20-122748 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 201296076 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 8-K 1 tm2035413d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2020

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

Ireland	001-37977	98-1341933
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

10 Earlsfort Terrace

Dublin 2, Ireland, D02 T380

Not Applicable

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: +353 1 920 1000

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

American Depositary Shares*

Ordinary Shares, nominal value $0.01 per share**

AVDL

N/A

The Nasdaq Global Market

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) Ordinary Share.

** Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On November 9, 2020, Avadel Pharmaceuticals plc announced its financial results for the quarter ended September 30, 2020. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Exhibits

(d) Exhibits

99.1

Press release issued by Avadel Pharmaceuticals plc on November 9, 2020, furnished herewith.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2020	AVADEL PHARMACEUTICALS PLC

	By:	/s/ Jerad G. Seurer
		Name:	Jerad G. Seurer
		Title:	Vice President, Legal Affairs & Corporate Secretary

EX-99.1 2 tm2035413d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results

and Provides Update on FT218 Development Program

·

NDA for once-nightly FT218 is on track for FDA submission by end of December 2020

·

New market assessment data identifies a significant potential market expansion opportunity for once-nightly FT218 beyond existing twice-nightly sodium oxybate patients

·

Management to host a conference call today at 8:30 a.m. ET

DUBLIN, Ireland, November 9, 2020 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.

“Over the past several months, the Avadel clinical and regulatory teams have made substantial progress in advancing FT218 toward its anticipated FDA approval for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. The Company remains on track to submit the filing to the FDA by the end of December. We are pleased with the progress we have made despite the challenges of a global pandemic and look forward to updating our shareholders on this upcoming regulatory milestone for the FT218 program,” said Greg Divis, Chief Executive Officer of Avadel.

“We recently gained even greater insight into this evolving therapeutic area including the significant and growing opportunity for FT218. Specifically, we completed a comprehensive market assessment, which provided current and critical prescriber and patient insights. A key finding is that six out of ten sodium oxybate-eligible patients are not going on therapy today, with twice-nightly dosing being the primary reason cited. This finding suggests there could be a significantly larger potential sodium oxybate-eligible market beyond those currently being treated with twice-nightly therapy. These insights, coupled with patient discontinuation rates of nearly 50% within the first 12 months of initiating twice-nightly therapy, underscore the unmet patient need and opportunity once-nightly FT218 may have in addition to the nearly $1.8 billion¹ twice-nightly sodium oxybate market. Based on our extensive research, we believe once-nightly FT218 has the potential, if approved, to offer a meaningful treatment option for patients switching from twice-nightly sodium oxybate, as well as those patients who previously refused or discontinued twice-nightly therapy,” concluded Mr. Divis.

Third quarter and recent company highlights

·

FT218 NDA is on track and expected to be filed with the FDA by the end of December.

·

Completed a new comprehensive market assessment that included a review of over five years of twice-nightly sodium oxybate utilization and interviews with over 500 critical stakeholders. Key findings from the market assessment include:

o

Insights from over 150 sodium oxybate prescribing physicians show that 60% of sodium oxybate-eligible patients are not receiving sodium oxybate treatment today, with the primary reason being twice-nightly dosing-related challenges.

o

In a survey of current sodium oxybate-treated patients, once-nightly dosing ranked as the most important driver of their treatment preference, placing it higher in importance than efficacy and side effect profile.

o

Analysis of longitudinal patient claims analysis demonstrates nearly 50% of all newly treated twice-nightly sodium oxybate patients discontinued their treatment within 12 months of initiation, including about half of that group discontinuing within the first 30 days.

·

Supported a recently published article in the peer-reviewed journal Sleep Medicine highlighting the lack of evidence linking the sodium content of sodium oxybate with increased cardiovascular risk in patients with narcolepsy. (https://doi.org/10.1016/j.sleep.2020.09.017)

·

Additional subgroup analysis of the REST-ON study demonstrated comparable, robust results for FT218 in narcolepsy patients both with and without cataplexy as well as those on concomitant wake-promoting agents compared to those not on wake-promoting agents. In addition, results of responder analyses for the Maintenance of Wakefulness Test and mean weekly cataplexy attacks further supported the potential clinical benefits of FT218.

·

Continued progress of the RESTORE trial, an open-label extension/switch study of FT218 as a potential treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy.

o

29 patients have been enrolled and initiated treatment or are pending treatment initiation.

o

The majority of these patients switched from twice-nightly sodium oxybate, many of which also completed the REST-ON study, and nearly all are on the same or lower stable dose of FT218 compared to their prior twice-nightly treatment.

·

U.S. Patent & Trademark Office issued the second U.S. patent covering once-nightly gamma- hydroxybutyrate formulations, including FT218, with an expiration date of mid-2037. In addition, Avadel has several patent applications pending at the USPTO, which the Company expects to result in additional issued patents in the future.

Overview of Third Quarter Results

As a result of the sale of the sterile injectable products to Exela Sterile Medicines LLC, which closed on June 30, 2020, the Company did not report any revenue for the third quarter of 2020, compared to $14.2 million in the third quarter of 2019.

R&D expenses were $5.6 million in the third quarter of 2020, compared to $7.5 million in the third quarter of 2019. The decrease on a year-over-year basis was primarily attributed to the completion of the FT218 clinical study during the first quarter of 2020, as well as lower headcount due to the restructuring activities initiated during 2019.

SG&A expenses were $8.4 million in the third quarter of 2020, compared to $5.3 million in the third quarter of 2019. The year-over-year increase is primarily the result of higher stock-based compensation, professional fees and market preparation costs related to FT218.

Net loss for the third quarter of 2020 was $11.7 million, or ($0.20) per diluted share, compared to a net loss of $8.9 million, or ($0.24) per diluted share, for the same period in 2019. The increase in net loss is primarily the result of the year-over-year decline in revenue due to the sale of the sterile injectable products to Exela Sterile Medicines LLC on June 30, 2020. The decrease in diluted loss per share is due to a higher number of shares outstanding resulting from equity issuances completed during the first half of the year.

Cash, cash equivalents and marketable securities were $231.6 million as of September 30, 2020. The Company has convertible debt of $143.8 million due in February 2023.

Conference Call:

A conference call to discuss these results has been scheduled for Monday, November 9, 2020 at 8:30 a.m. ET. To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13712485. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About FT218

FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. In March of 2020, the Company completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Footnote: 1. Annualized Xyrem revenues from the Jazz Pharmaceuticals third quarter and year to date results reported in their press release dated November 2, 2020.

Cautionary Disclosure Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the planned submission of the FT218 NDA to the FDA and commercial launch of FT218, if approved. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risk that we do not file the NDA for FT218 on a timely basis or at all, the risk that the FDA does accept such NDA, the risk that such NDA is not approved by the FDA or such approval is delayed, the risk that the RESTORE study may be delayed or may not be completed at all, the risk that commercial launch of FT218 (if approved) is delayed, the risk that the potential market performance for FT218 (if approved) may differ materially from projections, and the risk that the impact of the current COVID-19 pandemic on our financial results and results of operations could be greater than we anticipate and the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which we filed with the Securities and Exchange Commission (SEC) on March 16, 2020 and subsequent SEC filings.

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Contacts:

Investor Contacts

Tom McHugh

Chief Financial Officer

Phone: (636) 449-1843

Email: tmchugh@avadel.com

Tim McCarthy

LifeSci Advisors, LLC

Phone: (212) 915.2564

Email: tim@lifesciadvisors.com

Media Contact

Patrick Bursey

LifeSci Communications, LLC

Phone: (646) 970-4688

Email: pbursey@lifescicomms.com

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME

(In thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Product sales	$	—		$	14,229		$	22,334		$	48,220
Operating expenses:
Cost of products		—			2,823			5,742			9,711
Research and development expenses		5,569			7,539			15,156			25,160
Selling, general and administrative expenses		8,423			5,316			23,431			22,520
Intangible asset amortization		—			205			406			610
Changes in fair value of contingent consideration		(69	)		627			3,327			2,384
Gain on sale of Hospital Products		—			—			(45,760	)		—
Restructuring (income) costs		(226	)		1,866			(43	)		4,600
Total operating expense		13,697			18,376			2,259			64,985
Operating (loss) income		(13,697	)		(4,147	)		20,075			(16,765	)
Investment and other income (expense), net		213			781			(906	)		2,548
Interest expense		(3,259	)		(3,125	)		(9,686	)		(9,293	)
Loss on deconsolidation of subsidiary		—			—			—			(2,840	)
Other expense - changes in fair value of contingent consideration payable		—			(139	)		(435	)		(496	)
(Loss) income before income taxes		(16,743	)		(6,630	)		9,048			(26,846	)
Income tax (benefit) provision		(5,040	)		2,234			(9,258	)		3,641
Net (loss) income	$	(11,703	)	$	(8,864	)	$	18,306		$	(30,487	)

Net (loss) income per share - basic	$	(0.20	)	$	(0.24	)	$	0.36		$	(0.82	)
Net (loss) income per share - diluted		(0.20	)		(0.24	)		0.35			(0.82	)

Weighted average number of shares outstanding - basic		58,213			37,436			51,206			37,382
Weighted average number of shares outstanding - diluted		58,213			37,436			52,849			37,382

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

	September 30, 2020			December 31, 2019
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	83,109		$	9,774
Marketable securities		148,467			54,384
Accounts receivable		—			8,281
Inventories		—			3,570
Research and development tax credit receivable		3,058			2,107
Prepaid expenses and other current assets		47,054			4,264
Total current assets		281,688			82,380
Property and equipment, net		373			544
Operating lease right-of-use assets		2,866			3,612
Goodwill		16,836			18,491
Intangible assets, net		—			813
Research and development tax credit receivable		3,608			6,322
Other non-current assets		22,264			39,274
Total assets	$	327,635		$	151,436

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Current portion of long-term contingent consideration payable	$	—		$	5,554
Current portion of operating lease liability		520			645
Accounts payable		2,660			6,100
Accrued expenses		16,398			19,810
Other current liabilities		3,431			3,875
Total current liabilities		23,009			35,984

Long-term debt		126,520			121,686
Long-term contingent consideration payable, less current portion		—			11,773
Long-term operating lease liability		1,968			2,319
Other non-current liabilities		4,938			8,873
Total liabilities		156,435			180,635

Shareholders’ equity (deficit):
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; 488 issued and outstanding at September 30, 2020 and none issued and outstanding at December 31, 2019, respectively		5			—
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 58,243 issued and outstanding at September 30, 2020 and 42,927 issued and 37,520 outstanding at December 31, 2019		582			429
Treasury shares, at cost, 0 and 5,407 shares held at September 30, 2020 and December 31, 2019, respectively		—			(49,998	)
Additional paid-in capital		565,440			434,391
Accumulated deficit		(372,909	)		(391,215	)
Accumulated other comprehensive loss		(21,918	)		(22,806	)
Total shareholders’ equity (deficit)		171,200			(29,199	)
Total liabilities and shareholders’ equity (deficit)	$	327,635		$	151,436

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities:
Net income (loss)	$	18,306		$	(30,487	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		1,297			1,690
Loss on disposal of property and equipment		—			478
Remeasurement of acquisition-related contingent consideration		3,327			2,384
Remeasurement of financing-related contingent consideration		435			496
Amortization of debt discount and debt issuance costs		4,835			4,424
Change in deferred tax and income tax deferred charge		(4,582	)		1,333
Stock-based compensation expense		1,705			177
Gain on the disposition of the hospital products		(45,760	)		—
Loss on deconsolidation of subsidiary		—			1,750
Other adjustments		306			(667	)
Net changes in assets and liabilities
Accounts receivable		8,281			2,026
Inventories		(1,352	)		2,465
Prepaid expenses and other current assets		1,759			(1,859	)
Research and development tax credit receivable		2,036			(749	)
Accounts payable & other current liabilities		(4,051	)		259
Accrued expenses		(6,625	)		(2,379	)
Earn-out payments for contingent consideration in excess of acquisition-date fair value		(5,323	)		(8,640	)
Royalty payments for contingent consideration payable in excess of original fair value		(866	)		(1,374	)
Other assets and liabilities		(3,337	)		(1,399	)
Net cash used in operating activities		29,609			(30,072	)

Cash flows from investing activities:
Purchases of property and equipment		(33	)		(29	)
Proceeds from the disposal of property and equipment		—			154
Proceeds from the disposition of the hospital products		17,250			—
Proceeds from sales of marketable securities		30,075			57,242
Purchases of marketable securities		(124,254	)		(23,814	)
Net cash (used in) provided by investing activities		(76,962	)		33,553

Cash flows from financing activities:
Proceeds from the February 2020 private placement		60,570			—
Proceeds from the May 2020 public offering		116,924			—
Proceeds from stock option exercises and ESPP		2,006			123
Other financing activities, net		—			(109	)
Net cash provided by financing activities		179,500			14

Effect of foreign currency exchange rate changes on cash and cash equivalents		406			47

Net change in cash and cash equivalents		73,335			3,542
Cash and cash equivalents at January 1,		9,774			9,325
Cash and cash equivalents at September 30,	$	83,109		$	12,867

AVADEL PHARMACEUTICALS PLC

UNAUDITED SUPPLEMENTAL INFORMATION

(In thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,					Nine Months Ended September 30,
Revenues by Product:	2020		2019			2020		2019
Bloxiverz	$	—	$	1,466		$	2,201	$	6,392
Vazculep		—		8,786			10,429		27,669
Akovaz		—		4,208			9,545		13,946
Other		—		(231	)		159		213
Total product sales	$	—	$	14,229		$	22,334	$	48,220

EX-101.SCH 3 avdl-20201109.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avdl-20201109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avdl-20201109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2035413d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001012477 2020-11-09 2020-11-09 iso4217:USD shares iso4217:USD shares 0001012477 false 8-K 2020-11-09 AVADEL PHARMACEUTICALS PLC L2 001-37977 98-1341933 10 Earlsfort Terrace Dublin 2 IE D02 T380 353 1 920 1000 false false false false American Depositary Shares* AVDL NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 09, 2020
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 09, 2020
Entity File Number	001-37977
Entity Registrant Name	AVADEL PHARMACEUTICALS PLC
Entity Central Index Key	0001012477
Entity Tax Identification Number	98-1341933
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	10 Earlsfort Terrace
Entity Address, City or Town	Dublin 2
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 T380
City Area Code	353
Local Phone Number	1 920 1000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	American Depositary Shares*
Trading Symbol	AVDL
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avadel.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2035413d1_8k.htm avdl-20201109.xsd avdl-20201109_lab.xml avdl-20201109_pre.xml tm2035413d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2035413d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2035413d1_8k.htm" ] }, "labelLink": { "local": [ "avdl-20201109_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "avdl-20201109_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "avdl-20201109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avdl", "nsuri": "http://avadel.com/20201109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2035413d1_8k.htm", "contextRef": "From2020-11-09to2020-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://avadel.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2035413d1_8k.htm", "contextRef": "From2020-11-09to2020-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-20-122748-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-122748-xbrl.zip M4$L#!!0 ( ',Z:5&7^0>P/0, (D, 1 879D;"TR,#(P,3$P.2YX M@X"'(J*\WW8>NOBT>W9U MY:"3XR^?D?FTOF*,+BBPJ(G.18BO>$\Y%!:0B-8P"D(:WTQ=$W"X/<\[/EX MWR_AJ<)]0I()I4=4D$D7B0J*DGH9;H+54*S?$U"5A#Q502/#B$T89$@B8*90 MXPSI^U[#-!N#&+B^$#(^AQY)F;'TEA)&>Q0B!VDB^Z!MZ:F$A+!2JZQ>PKDP M16[:K(C86))04\4F\*EEG[LI!8.?QC6R"]-<5;F)C>P&8F2MX6)E9.Z2H7ZB.27> I M>UT#*V?^!]>0[5])=(%I549V=+/\ [&]G4QK"S]S#QYIZ5HAEPN.N1G7DH;K ME&ULS9U=;^.X%8;O"_0_L-Z;%AC' M<8(MD.S,+C*>9&%L-DECSVS;1;&@)<81(I,!)2?VOR\IB;)$\DA*BI+,148C MOH=Z*3XAJ0]2'W_:;5+T0GB6,/II-#TZ'B%"(Q8G=/UI]'4QOEC,YO,1RG), M8YPR2CZ-*!O]]..?_X3$S\>_C,?H*B%I?(Z^L&@\IP_L!W2#-^0<_4PHX3AG M_ ?T#:=;N8==)2GA:,8VSRG)B4@H#WR.OC_Z?H7&XP'9?B,T9OSK_;S.]C'/ MG\\GD]?7UR/*7O KXT_94<2&9;?(<;[-ZKR.=\?53QG^,4WHT[G\M<(90>)D MT>Q\ER6?1HVCOIX>,;Z>G!P?3R?__/5Z$3V2#1XG5)ZTB(Q4E,S%%C<].SN; M%*E*:BAW*YZJ8YQ.E)TZ9Y&:=.@;3K+D/"OL7;,(YT6=]QX&@0KYO[&2C>6N M\?1D?#H]VF7Q2)W\X@QREI)[\H"*8I[G^V?!499(#$;5OD=.'NQF4LXG,GY" MR1KG))8'.I,'FOY='NB[:O=>YLZB5;RI;<\;- MLF;5"CDJ(K0\=?%Z,="@WY7JO]\G!QR M<5;=8CBTW1":+T6^EG*TDUU5MLV4JNMF6A!5;3&DU[22(*GQ4LT7XO"QM'"5 MXK6E$%JZJXJVVE(UW4H,HJIMCO2ZKC5(BOQ6]A>213QYEL/\KM*T9,ZKWF+2 M(*"A"0L$TQC,0T/KM:F_)^M$=CG2B+SZ)7)G1\,&Z%UW!IVV]=[!*@X"G2$. MP?ZC&83J**\T75"ZQ>D]>6:\"Z*VS#4[-I,Z,DU-4*18C(& E%I4BKUR\8^M MN+8G/-WWHF$H7=,!6-4!T61!,6+W!F)2RT,@9)D&&[BZ):'"Q(NL.!+!5A2,9YY:GQ(*.')$/IFB' MJDZ/)@N*&[LWD)A2C@I]**A8?[(%CJ[$%OC]GZF2^@"P*7'G/&D^!2WL+% M:Y]T2?,DW\N7]6ZVFQ7AEB*:$E>$0.84&7IZ$$0 IG022AF2.E0*/=:_>MI M<_FJ)%@H7>:6 [O)-@MM34 \6(T!3!RTQ9NK'KF8B;:*XW1.8[+[A>S!TADZ MMV0 -MMH:** V+ [ ^"HQ*A0(R'WB,<=3S:8[Q=)U--YF$*W@$!&VX3HJH 0 M :P!C%1JM)C/_/L,"0BS(3X!V%JA'\IW M7A"34XB*#)#,P2-W%W$L3E=6_7.=4#(%SX)5ZY:Q#KMMLBS"@'B"W0$45@L7UE0Z)R^H<"G_M$Y'8K.:=#H MG+X+'5'] ;0[,[%YRY?LU?9J.*CT HYIU8K-018>-(:W/F1D@!SGR!#_L!3# MKEM^Q]E+0B-X0 W)O6 #F+:RHVG# \ANL(^B>KBLXORC5 W<>_]@E,Q/B],V M:6]N2DUXJ+2-]38TI=H_&'H2L?C%@GN&GI[J8J6VP=IBHW$H- P>;(G*IV04?O7 E+BJ;\BC]?KI"1V1OT1IJS'E^W4W?P*B&(.M;=&-VW2O=2I[_Q M)!?'G['-9DNK9T:V-Q4!G:NZ[K2IZMTJ"H*!+FX%BP-(F2/*'K M7\7%*D^PK6PVD2LL8(.*"5,1!!"@+9V&@Q II1<4[CB10!)1'<4T1;E4$K]] M>+". KK$KM#H-ZP0@95!H-)K3T=&!(RC1@0J0U 1$P(\\RS;$OXFA"PAGD " MS0,X&?H0H8),]J)5!OHG;$&BK>@W]].3U3+)4]MEJ"EQUDL!YNH^2DL/@A# ME$Y$D8;8 YJ>_'7U-Z2BO$!PPY8EI6E2L4.BPJ&BR2((" M?>E,W#!425&I];?>5LNRI5!:NBL,K+84 *W$(*K>YLAH"%HU[K43N-Q%C\(: M :9&V&6N.P.;2;U#:&J" *'#F''A4DF1TOJ;&G'HRM;]@X.UM\'!NF=PL YQ M<+ >.CA8>QXOY$T_86R5[H@.&.4Q.4=&-MSIVZ]V_=R>FRW7\T!Q$% -<0A M\(*.#!H_R2BDPJK[9QYY^L;2+C<\@/8;'.CB0+BQ>X,X*06 MHU+M1<1GF= M!)H3^26-Y(5\P3FN'(*EAN2NIWUVF=;G>]JT 8'4:1"*%G5O!,V]>\156YCG9@/,N^D-<<334O**I M3Q\$4P--ZF058>W+\"(0R4C_*S,UE_J'!X MD>-QL\6@-FQN*((@!;0%#9J; M7T[PN3+@=I4FT57*,'Q7IJ5QO!Z@:4];"O @"(@#TQ6T & A1(72(P6?,7WB MV^<\VM]Q%A$BW^C*ZO:K[Z[=P&BWY+RI2&VF!H4&1-M;_ (<'K) C3P^-/HP M_[< Y8OKS_MQ#()0!>_K7(13(#;;B25XW. M2;N1@$Q5QN7XJO%YT+P>=/O]1F(LDQD32L)50ZK&7W_^_%/B?BY_:3:3'@>1 M723O5-KLRY%ZDWQB.5PD[T&"9E;I-\D7)@I_1/6X )UT53X58,&=6#5\D;P^ M>3U,FDU$M5] 9DI_?NAOJYU8.[UHM>;S^8E4,S97^LFU% M>_VS*GXIN'RZ\+^&S$#B8$ESL3#\JK'3ZOSL1.EQZ[3=[K3^^7@[2">0LR:7 M'EH*C4TI7TM5N<[Y^7FK/+LQ/;)<#+78M''6VKBSK=F=Y1'['4\,OS"E>[6TS2=#"_]?\J=:7>7ZHO.S+#31,+IJL%DF7-VG[4ZG?>YK?K5G9)=3UR<-]UVJD;3V M6IUJ,"!M*?36'=@K @OKNA)DFXI\^SB_++?>=-U1.DG3]ZHB=RVYCRO+M1L; M1X1*]]H6GKXZ$.J;-J[MDK&!]&2L9JT,>,N+]Q]*"LUV9TWXE3OTK6SN>FBL M9JG=U"?8$$39RC=GCHU>/Z^]0_Y"#/Y@ M?*0(%$'B/Z,<.Z)J2>-P+67!Q -,E:[!OV^)I/XK)?4J;:2P_RZ8MJ#%$L/[ MR!B)_#4E\H!"4NJ/FDG#/24,]F-K)/??2&]. AI)P0\F((3/^)A$]?@J>R3\ MWRGAAW6^&/PW,W\/X"X\^ CL%$$&X8^7$H0CM:1QN ?-5>8N^QH1@2-C)/MS M2O8!A2^ ^HW,L,RWINBLB1[Y@3Q2X#UN4B96?O7<,1.'7F&.!4^2K];*? 'P M_P6FT>AWC+'@25+8&HDDV+N%UGLN1<>9L#46/$GR6B>2A/R-M-PN_63"IR(? M?G\PNT_\V I+FB1A#8DB)+QY8B&MGRR)43ZTQ)(FR5-CX@AI=YTJS41?9K#X M ,L8[B-3+&^2_#0JCQ#XO>8YT\L!3^N'D6-;+'*2K#0ND)#Y(UOT,Z>-C_AJ M K(>?; (-@(D*2E*+F$@^C)5>JIV'D=W5>&^H>62^C$ E)ICIZ/H@M#1.:+@G_Z//BG>/@D.6RMS!<%_^QY\,_P M\$GRV%J9]/"[[N.=?E3SP/QWT!@+GB2/K9%(C[V\#MWI>ZUF?+56JX[]40EL M C3V[A8^BBL;P0P/7]CB:5.F.I6BZ.G?:^,9>(_/JV[YZRVQY(G3'IC0FD> M6J[Z@'_X$5K@=&""I4R2YU;*H0'KHZV!A;ORO@46*TGR6B6&A.JM\O,L$R6C M3WJ/K;!T2;+0D"B: =DO@S;!P6#G-'J-'RB#!.97S:WSHZORO)#K)SZ! M>;B *18R2>H8E4<"?* $3[GE*DTQ'(F20XC MTDA0[WE3#?G !(N7)"NLE$,Z2MPLT@F38PBOHZBVQ&(FR1)CXHC'Y#%J3!X_ MD4JS4['9-Q"MG*LQR63J4O'MCOX OE]?2EL&&CVC")%$TXB M? 4A/D@UEP-@1DG(5@E";!XA6 0;"\*YRQJYA('XHD3A6.ER\:H.?!\"IECP MA'.6 7F4*T57B[*W5Z;52TQBW$,EL/@))R_C8DE7T%GPGO,9O&.6K?V,12%4 M AL%PHG,N%CB70"ZZRY+8Q6?MS\PQ#(G7+Y;*8T0]2!G0KPM#)=@HJ/-@2$6 M->$ZW4IIA*AO!I3R@6O8_? M,\-2)LQ@*V010G[+Y),NIC9=WFN5 OBI&K/]_B'2*&0%V, 0YK;/0D'YP$'E MN=\JI=*GP<1)-W>%+5\)Z[R,/G:(EL,&B'+3*D(XZ9V2^;Z9#;*WRP<8@?8+ M)AYA8=^ZYI[B-TZ(XM@HD;Y]"8VA(EB7K2-=M^Z ?_OOZHS_Y=]PZX[\#U!+ M P04 " !S.FE18Q'39;@3 "4?0 $@ '1M,C S-30Q,V0Q7SAK+FAT M;>T]_5/B.M>_.^/_D(?GO7=T5Z M*(+*,PCHX@>Z@+M[G3OCA#9 M;2U217V MKW]/TA8*M.('B+NS>^^NTB3GG)R<[Z1A_W^#OH$>B$-URSQ(R"DI@8BI6IIN M=@\2+NLD=Q/_*ZZO[?<8](.^)CU(]!BS"^GTX^-CZC&3LIQN6L[G\^D![Y/P M.A4&D?T429+3/\[/FFJ/]'%2-RG#IDI&@PS=O(N'SUM'7=N.H4]TY4\"))GT M#&AHU<8#PIUWTE[C1%<6V77;Z\J"KCJULHJ<>XH.K\=HP""NK\QIAAF2'X>- MLW%W%MU_W#7-'&S2CN7T,8,UY)"VDY*25'9"0)*4J!. X'.J:SW,A;.;S,@! MG)G%F9PI;VYC.N*X1J;8'>"$!ABA2$E)#D%W2"<6^$X:6H..+DUV,;9'G3N8 MMD5'OR$"-K0XED%HY!C1$C%(M5R3.[_)YE$1SHQM )J$K:'ZKA/"FB@#?90 MK2)^N9&4_,U5\R^E8Z1/4X"1OH"VG4.0@,J- M?..;,X](>/02&,I-LX<=0F^4&V&]/2!4/'L)G JGY=*'E9DA*19XV]*&B+*A M00X2'5", I(EFZ&6WH@RT@P-$[0@4U_2$8I^D4^#XL(-,R MB6C4!P6N2\012BH^ZII&3%]G^0/H6W?[ $[U%'+ &MS8'3E67Q@%64Y*>6:- M?T\@$R8.V(A>B!361'$LK?OI"11OP^N)RD$"?$:A;8%EQ*:0XS!%$V*>*(KV M&"+2D^S@1($E)PZ$&(0&G;CC*% 1$0!]2+CY0D_X VXXDH&ZIP942_C-#,S; M08+JH 7$,VDC?%,(/)S4>9$I@?8-A1*S(Z.GHN:[QEHY. M'"1F0R(];KEV.KEZTX/'Z-*1^'QL-O#9TF:I@+#'814P#<7Q% )(X[:98;"D M,8."EFFR)@@('OHLG>2S:^H>DT$[9[C9)YBZ#BGZ:ER /@&PH&D2!8<6 ]^S M";$H?":(3J_&,;8],WC 3L RSO*6CQ6*@9GEA)I?SH-I&J.@AI!6B&GU=7,> MVOE\F<8;!3AHG^!"%$/3,QKIV8G BNZG 03\Y/_MVX'E[6.GJYL%)"4@_K&+ M\QM#OJ3A&B1YB;O"'8?-N3H<4\"?4,G1M#_F- 22O71ZW. M1.J13%8LU>7A&$_Y;M11EC3.EW[^4_[F/OY\Z.+M;N8MR@!^H%&MMU"C>GG1:+UUY=]"B:>1(93!6HD.EZY# M76RR]35F 3:59^!(SB#+&7_:WM V%Z0NRYN(U4&L1SC1KJ,S'8BH#M0>-D'. M2BI#T"SG,]E53V..4"[(",PPJH/[NC$LS"LC )-Y%K6^!MQJ$-MR&-K@#SCW M"(80F5"&R .@08YH)MIF 7G,]/@Z9?US4];_4J1C52]9BW8#)Z[=Q/*=>E16 M7^T&P@4"#3#U85Q/P\,A3(*846YB@K!$L6X]D'Z;..MK^2W$(<=ZC]]6AOXX MDFF.T[E1/3[L/[9WS:[FW@! J"F^B M6/I6JE3/T.674N.\5*Y>M6KETED379Z55QIA;50'&,P\IYY;*V=$-<(449NH MO&REK:_IP&%&$7@&L%[.YCL0]T==5ZJN#+<- HV& =*HBAUC*2$^VUC3@L\O M)B14;QF5453+,+!-@1_!;Z+XSIP _ -QF*YB(R 9^!K4Y_:9%O3R06GHW1Y0MIW*9% .&2*L#G*A,VIF:KE@)\7^S)-!JZQ[&TI MEBTMQ@0UZ,-=YNC.;5YU%^&^^9YP@6A=[-B.]>!O:$ZZ\&>0FBC6'&)@4WO2 M1/F_,BU^2;(K6!)Y8DGX=AM0#[%)-/^SI'/]T\'#A]+B7, 8)]\4D).97'YV M1^>EK%R%=)R67XQWF-J5GJ FP(->29I 69F8-N(3&CFBZ2RB=%9+E4E:U^7Z=TM434 M&DU4[=N&-23.AU](B*?TL'G=7!WCN"E"GIJLD(I)K45U*[49M8AI$7L4%Q#I M_ 91S0L6Q*=BFV]EA;;VEI8[/.UQ2YKF$$K]'_QTBASM(M1JG>6;@\:7N_;" M7$0$\D11EE 5.P8_!P<<((Z#U9FS#3/)U_NS48IB8QE^O7!:UJ,9S<2SQO"D M(5MW_[2SBV;B&'6B6'';!J2"2@S;MF;V,4J1D_%"S.B96,HA^V8ZM1)=2"%+ M1,)^ ,PG&!4$3Y(U+^J=G60F:I*7%F78N-;M^*!?NRL=]X87TG!PN^A%F\ . MZR8IJ)79C:_'>>+^9I_PWB9H>H-H^1CK%D,EVS; Q@Y9)D"FBL"U>4E,-ES,088=@4'@-6/(YKK+ K7 )^L5;DZ^WN>Z7"_/R MXOLB7$ 87Z*8V8Y+J6:,8=XG^,P"P;_D4WXJ/SS'S<,!^7%UW.@L@.AIG.#S M45Z1>& VS_3]\I5,SS3A&=.T1)P;1^!G(4/UJL>.<+OP$7L69POI'>1M)6KK M:Q3$G2 #TV /;/.WX/J?^O&[\)N[F$2QW"/ "KY=#6+N6.#.>*&D;0U0FQC6 M(Y>GT_GKV_+59]'U^GJ\E%*V=7,\LR>*FT'7^(WX[S!ES@;ZHDYCYW3H.Z?O MCLY (GA-RS7]>@2-]E"E0:/U\_SLY+ZRNY"-];B3]Y$D>6S;W8MU7I,_PKPM M^@"!R#!$9/LG5[AD<]N LLJV+]-3!T'X^8\-.8?*1PVD9*04=-R,BZ?IC/&@12:E/<(&_)36B(,L)F*KW MO:9"V.)OQ'N':=4>4@U,Z9/ERB?39[_1+V7&-<>^VA4Y4651$W6P* @VA_VV M96S,JO(<^"*8QFMJ$HJ5QPL'EFE,SQ;R7G$UT ,V7+*^]G]22I*1S=_NYAT^ M?8K?#5N@8JU 8H+#T;ZE\0Q-S)$X2NR'*[->DQ9Q=&L"(3\.73E;M5#4TZ5W M6>:%V,QYJA^$8?&GW+5\_DIEG:_#Z]?O#\T<,06LL[OJ432!]0M?X4;Q=A\!"U"2+\K7J(P374'J*([NMK#:(2 MW68TA:K<:<:"Y)LK !A$BB*^V[@A;Z))XY=:V&3?I>;_Z1/B^UH@>(AY)F0+ MM5T&DS.&2.?53=/T7[A[U%E/!-D&A _04;R/]03S84B<3/YB3*J9&L_9"!(.$$ZM8&A4P3\@(2/0P4N=1WK$3@'N9_-=S4P11KIZ"9((_#7 M*Q%+VVCV1<'Q^X$9M,%GF=L39>*@LR[>%['Y^R)\=]!+()5V4IF%M;X6]=;A M""K/)L<#0W!_F742?B11K/I,1U,\7UZ18_+L=H#_6* O>]AC3I3==FUF?CG> MOEYJ>>,)NEY8V5CFNKV'#G?"6CDE(%N@BI$J[FUYKJ^%U+L'"DP,L(F@P*8E M:A$N)4+A *G8!D7B/D!=6$WOJA]A8#DR8\BQ"U/*!=.$^4"+ QZ*PC@P"]A4 M>:$>J^)0'>_,+V/4L*.!%HL-4"VZ$H+DS 8>%4+"^IY:H/P'(K,4V5BX("SX M2ALYG*T_YTZ;>1%MZ,Z;E1\[B.851[$'_>]='D !6 ^?B.9GIQX;KX5*Q ME[0U,G?VDZHV+DT]'T5$$2N&87R:VLL1!-LI"3^5>@N,5&Y[>CT]Y_7*Q=QO M%_F5E>'KRZ;_*"E)F7EMZS5S6*00BC.>U#48?8KTJ3_@^"YLXOA;*^ R04D# M;UJVP+U[+WA-OP(*E:/(-E18"!,"&9Y[\Q?N]/2VSGR2 M\RG9.W0&G?W+1"!VXF?:O Z[R=/4XN.:WU4F6CPXUL>WY/*4]BG6"KV<71#, M&%;Y:=?/CA#CZ:S?6UX'721XCC$77;MX H M.-QHZ+BM&QYX@1!#7.01PBOECC\=G<\&^9,9O]GH5:U&-[-R#O/,P3]**3:* MU]>>*!U8L_O(6WQ7B-CB$@HR$#K$#VH240>"S 3P^7=3J).(J:OV?,P?74G^ MA"R_:\B23TERZB/&++Y=HW.#C(^G+2LC9T/;]"@:,^^#4/;'K*S2K,19%8R\ MV\U97Y$RVUDYH\DW9)#/)^54C_5?O=@\"ADM-5ZX25D2U9?<<[\@11K'R=3U M-\/B W=Q@T!DM#^.Q7BXQFN9J6G>_0(F[X\FKU:37[>6LI3]4&Y??*?("U10 M% QK_$0"5L4+PA7,,!+WAVQP7=-XRL-52B12O"O_DB$DOL5$\V^%W$PM/[IX MET+\='%9>??B\IL*QY.8=V(V#%9?7OZ8(>,S3^D\._INUH[KI=95([A4_T.' MD0MBWF@;(!5]EO^9843XLF7O,,.]JSOBR#I]9HED:_H4!-\F5;'+=S5%0?&24LG-DW3 MZ 0B6PT=I^"9Z\R[17!5(C%YD]+JQ6-$3^:OIU_>>_D$7S\_\06"BYU>5GD] M.;^$8'T$85J,!+U^2Y"_K;(8N7DU#=]TE2!>'1-?#;B%SD@7&ZC4Z6#=H>AO MW+?W4#G87UM?@]C6(?SH\K(/Q7^,'.+)%SR??Q'/=/:>V4,7MCA]44!G_"*B M#Y/,+^W$UJM8F.9?IBHDBW^I<'']>5_=NGMX(XZ7BNMO0E_Y2DX&1[=7U=/' MN])YXRK]]2+;N-:WY>\[][7<6=/6CYIW>MM2%4,]4JYN3V[E9GV[N:M^/__: M*.\^I,^.E)I>=UK?*ZT3U;B[NCA1AKG&;;]:ZK.[>OG;3B/7UFQR:':_:>Q+ M\^&V]W#UY=K]>IVO/@[-ZQ^?+V][N7;[Z/2KFJLT:WAP>-*_V_WZ^)T,CG;S M_PS.G2:56O?TV#@UN\-Z<]"X[V3K/[+9^Z9ZC8U\1>J9U_BV9C>.SK>'_<^U MZT:KTOWAR+6S[>OA9?W\\.2B5W*.>J[9Z?3/F"R?G]X_:M>FTOB2U]*E0\FH MGQQ^/3CP6/+_4$L#!!0 ( ',Z:5$78,S!)2H ,OX 0 6 =&TR,#,U M-#$S9#%?97@Y.2TQ+FAT;>T]:W/B2)+?'>'_4-LB;L<-J%29E9F5[_STM?OM M\O3XZ-/7=NL<_DOP_SYU+[J7[=-/[^5_X=OWZNM/GZ_/_T,ZW?]BE4T/F4OD!)1WNV_UW\" \>A,_%_*?89$Y]JW[@?CV M[2#\2(;,O[7=8NB-/I#RY)\]+PR](7SR[O33Y]/VSX'=LT/2;):T3^\_P_9N MYA9>=T/Q"V!E^"F\+[DCD[LA]]^=_NKV@M''%W[)IR_75]UXY1XS[VY]+W*M MHNDYGO^!/ SLD O@6_?,XL[QT8$Y#L?>7X8D.[ ]BWROQ'S M85VBE_4R^6*[S#5MYL"/@L@) XDT?.,2W"WN[B-Y+JCJ_$;AX@F.PF< RUP+ M(/6]>]N"E_X862SDQ'/)EZZN-<@YO^>.-QK")@G\Z-9GPT.Q^ MCU>^Y[X@A/CDX$'DMD_=\_@7#[85#N#!DEZUW7?(T^>GCWR=/"+<=K'/AK8S M_D ZXV'/

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

W.E;[*3@ MF"6-<)&D0!:!Q! KQ)<(<+U(J8]O.;+U);?\6IL3AK"#&(T(!Q X5UGR")(2 M12PF;S?";##ASL>?!)C1C%4-ELR>1X@GJ9[\KPB-,]35T$,8)(RJ!?F(84H% M\/$18B@[Y'[&@@'0)OROP,@]'*UP&4VY7YPIZ/21+V4[BCKRBVYHI=I$:#%! MQRN*ABE1KSB\1&>+9S^%][S@?/&D]I8(SNX M!Y7Y;%I*=P;6^H=L*#]"3I8^D=B7CV0A7& !.D8B](&AI/L&EB0F M/,V7TZFJ+V64+I0= LF!6##16ZH4HYE]4%4AY_E(Z2A+W'M;76<6NET+C7K] MA%3*]6*SKM5(0=BRP!)R_3/F,HN="$D-]W61DWWLA%@-97@0*1;$'JJM%,672\H;VWU@9A*F/O.<5I[O" MJFO8DZ&B=$*+%+G84@[-9$&R/A=>?!79G5AH+UO<.JUY$M?B+< C<'#MCS!1 M\]R/;LFY*-66IS!)+1=WU1?/DT$D\;N6-02+7*0#X$\+7\Y;)V1ID>Y\>:V5 M> -:/)-MJ) "8#8*A!XW&(\\O-+C@L))51G>"K$# N,;D3!:_-B',!O]>+PT MG3FP5VL\J?DZ/E+U(%]4&Y:)880)]]*M*VAL)%*+,'6'SFX,#]>/[0B?#45! MH;Q+@1X\TTZ4 0[X)!V7W\(1NX(F9!;VI/(KWEIL!1W$;?8\P;>\;P&89HZ9 M,?UU-:!DMCF#$II\R/$UMZ1G>Z.9I^+6#3.VT$0SBK/X15\'8DLA9"6Z2"$G MSY;8QQ&[I_L]/,%3V[1[.#YZ- ?N"W#DT!/J->XA]C3)ZT"HLF16S0<*%<4GAHT%#! MTXO-)^GWYY:ZG$3<%H\KOGPM(<=FK2A=-24IS31I22OF9]O3_1D!O??'TH9F MD:![8*!S,"X=+XB YK[S6\S9Q+BA;+90O/2\.U'SW@D!&T/9Q&B'7?I>#>0U M4Q"D/SA)!:K&+""J,X)J0U%T)&8P)4 A)BY)3J3?JYIJZ>@19J8BHWHK-@8[ M4R]1RPS%]:@U#4.0[>PS6GO),^V?)J@V8"3(APD\6XGK[%=O5?FB1?EWY*LH MJXK1JB"R*BOO!T(5Q*BR3(V\M1'U7@]=ER#O@DEJ(7IK71G/A;^G+6I =1&2 M3!;4^%X@ L'"9^N)3$%AP08ETHG,P?R>,3=SLFEU%)3TX$:-"\ <>ZC<$#36 MKEP4S8FN<3-Q'2RB370T$;+9&$E)#8+JID+NYC<%""MI^7R0BT*O"$Z1 *$ M_!$$*T?$I%F9%9?A1C)UY &,5=1EX65L0EOH$)A4MJO/0.F:=B:)/Q0M'>9_ MJ=H S'\L3W7^TV1+E?GOX@+C^<]O(]L2Q[BPGVE;FX6W P,.EWP.&/USR;9< M8%[TCX\FW"2+JH8VII #*+X,N 0B9T=JDB['2QQ(4?:[ .06Y*%AE@*HV2?I MOR*WDEK7D2\2>%>1(G)*+^XC$9^'U$I 7P<#5.KNP@+!WXH>/0DAUL-W"F,+.$ MSBQ#YE?Q1:,E)!;DVV3W&*PHD(2 T5=L'B1%$8T;GT@>=(6=&OEQQ5Z(4=&B^#+NUBFEIPBTHWZ+;5]$?!VS*T,B',3Q6JJ6/!:QEH?49IH<77$(/BQ) MYUXW9]>\7YT6M.6VTI9K,+/:6D_U&IJPQY81)9Z&X M*Y2HAP4BFMX'4BK$VY*+82<[/\1* ]1@+-5\*=;#XZO@.X*AN"&^#!*^^AO0 M[E43P;B9(- VT5HQ^TKS =.H4,T7G88!T_*G6KGX[XGS0Q@'LE7>;%=90Z,B M1ARG%CV(EFA)WT9"$4/ )LH8&*M*^3@^*G3:9R?X^H333JLE>O!A&SGA 0$ M_%1U73N,!C9KN/2-W*6?19?^EY57"ZCL(\ K4+PS5D%NX9IALN/?>*IC" TD M[HD&UCJZ266G+V60)*1C"0PT@_;S_B.8 %02@''W;L!X"E+^+@;/R.W;^B"Y?F-_-K M=#O8\=JR1>2T.[]J$;G#-]P,/!?$5*%FU$Y(I=(L:HV*L?N2W'QM??_6.FO_Z%Z>=+OSG6_NJVR'77TCA\KK3.2$75V?7W]K; MBJ-E(*ZW\8O3P@6:X5X4@'J>T&*G2<0XA>-$QK_V@5K8X0\7L_Y";JW8QNM6 M3L:FDI0(8"8Y;!0 V\9_841(%"MB;>7Z^)#UD"LK)B52WL5\/*V,%#6,@?TW MER^9 C5;0#GW,[FOX@/' #BN[E@?R0@+]-S;J8"96V[Z[K-K1,G5/]_5WCWG M!W6'FD'>%)0K[P!T6;6Y&SZMD MRAHTOL:CNSHZ?5X.K#B"]3:P[*:3LU">!G#'I)XQ'&K-'(X?AZ](AVN* MWF4=#?S;7D$O5ZAN-*A>K9XL$<]*MZE4_K%D9TF8'-X'S-_(%$]1#Q>L:.J@ M+RZUXLAFG]/6V\(O*UZKE9]Z7LPUQ582%@L&"Q3ZO%TLI_(#P8 &)*$O4/ ; M0H"N4\.HO&$$5$ @+-X#FR-@"R'UAXQ(/64(+=O!M8QEN[>3JO0/3ZCZCQ_" MQJ>^EMAY_I//>&4.6 [8ZP+VLGI)K#KA>[%/E(:-HI;(U#-L#._U)Q7X*4;Z MY:HD3XGA^ K&C02D;O64/+)$L9M&)L>]&F$C"=5A>]!X>L05RX(7/E MC#)LBA 2-O1@-W(*7GH/(L,V1;F:0:@JY2S*N9J65;WA3-2#B';&?6;[Y)XY MD:B7$MV;R"*V5%VZB71#?"RAXXH6VBWU\/I#B1'SO6*IWL1UG MW%IAFH[RQNA",VBMN6"\Y%+I.2AL4*.>"_9M4*B#)K?@ZL@Q^ P,UBJTV5AP MO^Y9P*^AJN]8UB?S"PLXBN.$2'4]O0958;D(/FPKL5"A6B5C,.EE6JYG,<)1 MT&JT7ML$LI,4.OED2Y-)/V+9\%(* 5)02MX)Q9E#Z3T17J&Y M48 PS8*.5BN-3#KX1-( QWF :YI[^Z0K8YE2?-B4!3#!464,IB:M-3(F 0 F MO;G)%91&A>!2S"]T<5J?YPJ3:CID(.H%MF4S?YS>L\AN?"R'[/ @*^BT4=DB MI)E.O6"%-^A:-LN7F@(I$O.YJ46P[!@;;[\Q9]0*\L\=>L^)=6F+M1AYL&OM M..'.7*%O#W?-74?X]U-H7KA,N'^);.P7_RMD/]-<-"(<=WG?#D^P-AU'OSV9'9XY M\5\%DMY9HLA;NSQUH-J%C.E<[7T._36!Z1=$:DY_ZV'/H+7*0HPEI5E>&XAK MO53%X[GBX;."^RL7>O8YB^?4!.?-FCYMN^Q$0]1HO?QD-J18^(4XY?!QV*"- MVI/2.D?A(RC$U+?%Z.?F*-SPRCMX/!:,,JTTGDS#?#8MOJP:_IB]DDJS9H,G M#\->RP%[DX#MQ[&VH'XE!A44Q8A*\Z7QOB"'UQ*RY=)!>W/^T,32;%.>F M$YIRR4AOEX5-SZ>Q22.Z?=SVQ/\0HREPN#J\!V?,N1$.'!(YCWB%!\2+PB!D M+OH77DMKW_P(J@!Y)DLBC#JMI%CSW>+$-*IGLG$:G)BQT>7^NH;[\T5 ZE7Z M7 @<&F!53!;.8D?I70J!]V+DY2E.OTSC#-CU!OM6\\&^^6#?/0[V_=RZ;%V= MM4GG:[O=[>QOK]O-\MT5>>1#=+<80+C."Y:1TE-2;''J*UDVU_$PQN:^/+K. MN9G$EH;86IS@N.=!N5O1;!".'?@$&Y#:YK8(GUELN7@O1(D9WMMM\-E*V=-P M;++^:T=)EM!1J],1%TY:-=7<*_?*=O@6C]T*5TE= M2E&KK3D1^(P%8A$U";@9^79HI[ET3ZLT:*66Q6D U Q:K1_6 M3*/M9Z5BS:KI5,9(#>#UK04)F"N1V7O3G_S/.O!=IST(EBKT48F M\Q&U!JTT]^A@>NG.YC/CT(.4WX79]40UMLY23I6FE1WO4ZV<1>]3C1KZ'N_# M?;5E=CVW^+:-9?VEW"9O!H5&D^J+@?.4VLH;L(MJC"0]2QLRR<$W5S+T.JT] MW1 Z[U+UI/I]'ND-85 M+/:U];W]]?KRO/V]\ZL?_!5Y'TG[?W]<=/]#"N?M+Q=G%]T4M^/(B>[P=.1I MWK!CLY[MB/RX/'GX0 %+3Q; E*Y&GA_/RW(\6"CD_G#;B3=;G]-&/;G2[G+: M"*@JK2ZF'Z1:M&U#@=Y<1"86>BD>X%;=J!%9VL5=K;)MYZXTR;I) O KB:]M MHGJU6B;IB6KEC*9O G'Y$9]FSJ7W$+0:-9I9])%K3=K0]DA>KY.B>3V3C9FP M!]Z:6Y=6C!<9@_&&,-BH[VR$7OJ-Z+4R,M\N/^D&+2_65^8,]1R&JM+F8O5< M2B--ZZ8RI?W6SWU-AR>*<5Y[[&2R>"_%"4R:7J/9M.TU'=/PM\T 3%42T^7: MGDL*3P3!Y-97OJ?T'E;:G9I;D*%&ZULGS*=?RAV@2U.CS5H6W00Z-19[C!VN MV%L[?^[MFC85VC3R>K.MZLUH8U%(OU%7P=OE(ZU:HY6GD^QR3GH,AXWR.HF* MN9,@?;9T9@%+IQ!^=]K!7LH#SP&F"^)$.ZP"#L>D8/&^;=KA29X%=:" I2?0 M)MJ>]#EHR9::FD%!<1[:+ESV]\R)..:D_%(NE;5IA^^/I%JFY7(Y'K/!HG#@ M^? 2N 8JC0:Q@P"CP:)]2F("!PO)BA;1XJ>@KO-''EW>+ID2V,"(FZ%]SYT4 MVY-9' *W&[],2E,:KGUXCOGC9S'%2J[ R2X58T/&J.BTJ=?E%_)_$^L8=731 MKLZ4&G2YD9)4J\RVG?S+#5X#B,=(,2QSUO1=HG)1MC\/[UG4:T! M6U6R&(*K&!5J[+-7Q4NDV$;#R&$XDDY9:.E%?\&H@UJQF/.R/I>G$ZJF1G5M M$VT[S;)KA1\P27"J3Z4W'/E\P-T ;D^"P\W?F(>QH&NTJ>TLWO'T')FLH4^G MC<6IIENB+_T!0QG<"-9PN;TQ@M#J..;V19HMOAD<%O0FU9H[RRY]E8MJ T:: M:<61B!,*6^]%6.O@^TWDC3L.J'%')L;8UO(QMOD8VQ<:#?OB0"^9DDMFAN1V MNO"?;^VK;N?XZ/H+.6MUOI(OE]=_I&=>[HJYN*^TDQ^)^9CY>-Z73/=X:B3K MDL&AM7F,K*]T+KQK.0M=V2XGW^"W@X"T78M;2]SS6\*UKEJ:0OSK+X[_9=.0 MGXO?0X-XC6SCW5#4AH:.V+4-S(#"I3BANG7]"T_@077YP"&4?<=["$C?]Y+Y M\ S#7'E#HT,&[/6<6^HVK"^9U;ELDU<\)+9K>D-."N@)7K"O]SSZL[SFZ$^M M08U%EV0&9I^NBX "7,N5QL+XK>?M8B_AC?6S'5O6GU$08M/M@(0>=MOV7--V M.'9XGZ5B_!H_%)-]1[YW;Z,BTQOG4C5+@*4IKGO.1T"/MJRA1&X\EN7E2EOFU% M:)JDVG<^%/E\7$RZ $)C)A!7(#*DBCZ7606K2LG3>T@&-?0L2CT]N[/)%RBQ M;[L,M#]8ZW#I<$FI8 :HL-(\@)X9ZQL="3T.Z0Z[L>#=*SIEJF% \ EFVP,] MAA7:R";1T8J>4=%W-F @U<# Q811682%,Z>0])31B_^B9=\4>"\2U.L2&K5( JN:M:3Z)>CF+ M\DVK;ZNPIE2Z_<9 L'D8_>;*I+7CJQ8_&GB!J+Y $]>*S#1?K85*E=8WZDJ= M8LFV]_K-GGVKA5 #SOIHQCX5.*[4] MCBYZ2;%TXW,LW9\,FI&M5&:&@JPU!'C/JO"V;4'2"!=P4F,CP%ZO2/09$:F M,]\\UH[T[+2"WW7L> MY*6.V0 L#7)M::PE\LT!PR#+ 5:A%3;*V4VS$;11+_DT*H@WOF=R;BE1-LT- MS5/: Z$G[]QYU@S:T_?C6 M7\B@?L0C65 NR9.9OD'+C.D,GWB]1INUU\]X3#52#(-6JWLL\LS]DX>O.>S; M%Y0F_^2D@4?NGSQ\P-(@U]:SXK_PGA\Q?RQW+^8,CGS['C.)1G M\'1[DFIE M6JWG5OP!6O%(>]_8#-E%/<D-ZST310![?NKI)&R/9.=:\H_ +L MZ4&\D>KCP7W3CHMCVIV;F_0>DD[+F:Q)UC;*"$VMN).I:LNT.HJ]>+-K&.XU MNI-JS!2T;6:'IE6L7BUK++V,[K-[L%J]2:N+$_]RDC_=R$^:"IF>_@LS-\'W MIX7NW.'>!K/'E)U>BC51YW-?%<*751815_8.+'/7/2 MW4ZGDDG5M;+'9G0OXL-,/\ISX99VO%J M\>ZS531'6$C^Q=RIBUQ[:MS? 6OK35K?J&@PZU9,DQH;E=(?L$A^E"&>/0)S M@[-/S9SLAD$W\]N\%%>D!C.:3AL;]9%9F!1>SR>%YY/"7V@4=7*4=^?' MS$+#ZB/LD&#"?$XN%+)_EG=I9 MWINY )9F.\5JQT2,K+SGEDSR?FXZ54PO3\G/[L#GSQ[EO022=1*^,H>\3<:@ M[P1WF\]&7P<53X']G=]S-P)>ZXW)C:QI>BHG;U=GNI_1ZH=![_L9PI[C)J>; MO='-R[H/E*)1J2P;C+VL6].[T\^.]].&3?P]#^Z!3 A?D:;RAF:D:[2RV/;L M#<&O4^#6-PQ_C1K-!=_^YO"_@)M_35'T._O;C!P^2F\8);L=#QJTWLAB2%\K MT\I&[4/2#IA>I[7:'ELRKZ&-K,GVK3OOGBVH'^G!=':9'DZOO.U<]S3"U:35 M2A:C^)I!FY443L59R>@SIM)R[A?Y]4^"M+Z1> AQZ!4293T#*R ('TZ/K(9'K.4*]7X2*Y%\77P@5RR($Q/ZM3A)#"]Y-&]_WQ]_A]!;5^[ MWRY/_Q]02P$"% ,4 " !S.FE1E_D'L#T# ")# $0 M@ $ 879D;"TR,#(P,3$P.2YX&UL M4$L! A0#% @